zurück

Casirivimab / imdevimab (post-exposure prophylaxis of COVID-19 infection, patients aged ≥ 12 years)

Subject:

  • Active Substance: Casirivimab / imdevimab
  • Name: Ronapreve®
  • Therapeutic area: COVID-19 infection
  • Pharmaceutical company: Roche Pharma AG

Time table:

  • Start: 15.04.2022
  • Final decision by G-BA: 06.10.2022

Final decision:

  1. Adults and adolescents with infection with a viral variant against which casirivimab / imdevimab does not show sufficient efficacy: No additional benefit proved
  2. Adults with infection with a viral variant against which casirivimab / imdevimab does show sufficient efficacy: Hint for a considerable additional benefit
  3. Adolescents with infection with a viral variant against which casirivimab / imdevimab does show sufficient efficacy: No additional benefit proved